Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/135361
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The adaptation of existing antimalarial nanocarriers to new
Plasmodium stages, drugs, targeting molecules, or encapsulating
structures is a strategy that can provide new
nanotechnology-based, cost-efficient therapies against malaria.
We have explored the modification of different liposome
prototypes that had been developed in our group for the targeted
delivery of antimalarial drugs to Plasmodium-infected red blood
cells (pRBCs). These new models include: (i)
immunoliposome-mediated release of new lipid-based
antimalarials; (ii) liposomes targeted to pRBCs with covalently
linked heparin to reduce anticoagulation risks; (iii) adaptation
of heparin to pRBC targeting of chitosan nanoparticles; (iv) use
of heparin for the targeting of Plasmodium stages in the
mosquito vector; and (v) use of the non-anticoagulant
glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate
for pRBC targeting. The results presented indicate that the
tuning of existing nanovessels to new malaria-related targets is
a valid low-cost alternative to the de novo development of
targeted nanosystems.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
MARQUES, Joana, et al. Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery. Nanomedicine: Nanotechnology. Biology and Medicine. Vol. 2017, num. 13, pags. 2. ISSN 1549-9634. [consulted: 24 of May of 2026]. Available at: https://hdl.handle.net/2445/135361